US panel rejects Forest, Nycomed lung drug

US FDA Panel now says “data do not support approval of Forest, Nycomed lung drug Daxas for COPD maintenance.” FDA advisers voted 10-5 against recommending approval. Shares of Forest (FRX) diving on that news…trading AH at $29.40, -$3.06 (-9.43%) – Reuters

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.